SK Bioscience said on Thursday that it signed a memorandum of understanding (MOU) for joint research and development of new vaccines and platforms with Hilleman Laboratories, an international non-profit research institute.Hilleman Laboratories is a research institute established in 2009 by a joint v
AstraZeneca Korea and Abbott said they would collaborate to provide a more systemic treatment and management of diabetic kidney disease in Korea.The Korean unit of AstraZeneca and Abbott Rapid Diagnostics Korea signed a partnership agreement to improve the treatment environment for diabetic kidney d
Introducing immunotherapy Libtayo (cemiplimab-rwlc) in Korea, Sanofi has selected cutaneous squamous cell carcinoma (cSCC) as its primary indication, for which there are no competitive products.According to a domestic skin cancer epidemiological study published early this year, the incidence of cSCC
Boryung said that it has acquired all local rights, including sales and licensing, concerning Lilly's non-small cell lung cancer (NSCLC) Alimta (ingredient: pemetrexed) for $70 million.Alimta is the third drug Boryung bought from Lilly, following the acquisition of Gemzar, an anticancer drug treatin
Shinpoong Pharmaceutical said it was redesigning the phase 1 clinical trial of SP-8356, a treatment for intractable cardiovascular disease, in the U.K.According to ClinicalTrials.gov, a clinical information site of the U.S. National Institutes of Health (NIH), Shinpoong Pharmaceutical terminated the
SK Bioscience plans to work with Coalition for Epidemic Preparedness Innovations (CEPI) to secure mRNA vaccine platform technology to quickly respond to infectious diseases and use it to secure a diverse vaccine portfolio.To respond to Disease X swiftly and solve the problem of vaccine supply imbala
The Korea Exchange (KRX) held a corporate review committee on Monday and decided to maintain the listing of Kolon TissueGene on the tech-heavy Kosdaq market.Kolon TissueGene's shares will resume trading on Tuesday, ending the 41-month trading suspension.The KRX had suspended the trading of Kolon Tis
Spectrum Pharmaceuticals, Hanmi Pharmaceutical's U.S. partner, said it has released Rolvedon (Korean product name: Rolontis), a new long-acting neutropenia biologic drug, in the U.S.The launch follows the drug receiving marketing approval from the U.S. Food and Drug Administration on Sept. 13."We ar
Competition is heating up among Korean pharmaceutical companies, including GC Biopharma and Jeil Pharmaceutical, as they successively released four-drug combination treatments for high blood pressure-hyperlipidemia.In the domestic hypertension-hyperlipidemia treatment market, a series of authorized
The U.S. International Trade Commission will likely announce its preliminary ruling on the dispute over alleged trade secret theft between two Korean companies – Medytox and Hugel – in November 2023, four months later than initially scheduled.According to industry sources on Monday, the ITC recently
Moderna Wednesday announced the new clinical data on its bivalent Omicron-containing booster, mRNA-1273.214.According to the data, the company confirmed that people who received mRNA-1273.214 as a second booster shot had a superior neutralizing antibody response against Omicron BA.1 compared to thos
GI Innovation said on Thursday that it has received orphan drug designation (ODD) from the U.S. FDA for its Merkel cell cancer (MCC) drug, GI-101.MCC is a rare skin cancer which appears as a flesh-colored or bluish-red nodule, on the face, head or neck with a tendency to spread quickly to other part
Pfizer's Ibrance (palbociclib), the first CDK4/6 inhibitor that rewrote the history of treating metastatic hormone receptor-positive/human epidermal growth factor receptor 2 negative (HR+/HER2-) breast cancer, seems to have failed to enter the early treatment market.Professor Angela DeMichele of the
About half of the patients suffering from hair loss in Korea are women.According to data by the National Health Insurance Service (NHIS) submitted to Rep. Kim Won-i of the Democratic Party of Korea, the number of people who received treatment for pathologic hair loss in 2021 was 244,609, of which 10
Jeil Pharmaceutical said on Wednesday that it has released its four-drug combination therapy TelmicanQ for treating high blood pressure and dyslipidemia.TelmicanQ contains four ingredients --telmisartan, rosuvastatin calcium, ezetimibe, and amlodipine besylate-- in one pill to treat hypertension and
Merck Biopharma Korea has become the second company in Korea to launch a treatment for non-small cell lung cancer (NSCLC) with METex14 skipping alterations with Tepmetko (ingredient: tepotinib).The Ministry of Food and Drug Safety approved two anticancer drugs targeting MET mutations -- Tepmetko and
LG Chem said on Tuesday that it would acquire Aveo Oncology for $566 million (about 800 billion won) which marks the first time a Korean company has acquired a foreign drugmaker with a new FDA-approved drug.Aveo was established in Boston in 2002 and has secured comprehensive capabilities specialized
Novo Nordisk Korea said Tuesday it has appointed Sasha Semienchuk, senior director of marketing at Novo Nordisk Japan, as its new general manager (GM).Semienchuk has more than 20 years of experience in various fields such as sales, marketing, research, and management at multinational pharmaceutical
Dong-A ST steps up commercializing two- or three-drug therapy by combining DPP-4 inhibitor diabetes treatment Suganon and SLGT-2 inhibitors.According to KIPRIS, a patent-related information search service, on Tuesday, Dong-A ST applied for patents for two trademarks – Sugadapa and Sugadapamet – on J
Affiliates or subsidiaries of Korean pharmaceutical companies have been announcing their plans to conduct an initial public offering (IPO) to secure funds for clinical research and develop new drugs.Most recently, Idience, Ildong Pharmaceutical Group's new drug development company, said on Monday th